Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Bristol-Myers Squibb600 enrolled

Overview

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Melanoma

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of melanoma Exclusion Criteria: * Age less than 18 years old

Locations (1)

Local Institution

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Prognostic Model of Overall Survival (OS)

The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.